IDSA Home

Update Alert: COVID-19: Vilobelimab

IDSA is committed to providing up-to-date guidance on COVID-19 treatment. In April 2023, the FDA granted Emergency Use Authorization for vilobelimab to treat hospitalized adults, specifically within 48 hours of starting mechanical ventilation or ECMO. This update to the 2023 guideline includes a recommendation for vilobelimab, aimed at clinicians managing critical COVID-19 cases.